['diabetes mellitus, type 1']
['empagliflozin', 'empagliflozin', 'placebo']

        Inclusion criteria:

          -  Male or female patient receiving insulin for the treatment of documented diagnosis of
             Type 1 Diabetes Mellitus (T1DM) for at least 1 year at the time of Visit 1

          -  Fasting C-peptide value of < 0.7 ng/mL (0.23 nmol/L) at Visit 2 measured by the
             central laboratory

          -  Use of, and be willing, based on the Investigator's judgement, to continue throughout
             the duration of the trial, either:

               -  Multiple Daily Injections (MDI) of insulin consisting of at least one basal
                  insulin injection and at least three daily bolus injections OR

               -  Continuous Subcutaneous Insulin Infusion (CSII) of any insulin type, with at
                  least 5 months experience of using CSII prior to Visit 1

          -  HbA1c >/= 7.5% and </= 10.0% at Visit 5 measured by the central laboratory

          -  Age >/= 18 years at Visit 1

        Additional inclusion criteria may apply

        Exclusion criteria:

          -  History of Type 2 Diabetes Mellitus (T2DM), maturity onset diabetes of the young
             (MODY), pancreatic surgery or chronic pancreatitis

          -  Pancreas, pancreatic islet cells or renal transplant recipient

          -  T1DM treatment with any other antihyperglycaemic drug (e.g. metformin,
             alpha-glucosidase inhibitors, Glucagon-like-peptide 1 (GLP-1) analogues,
             Sodium-Glucose Co-Transporter (SGLT-2) inhibitors, pramlintide, inhaled insulin,
             pre-mixed insulins etc.) except subcutaneous basal and bolus insulin within 3 months
             prior to Visit 1

          -  Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that
             required hospitalisation or hypoglycaemia-related treatment by an emergency physician
             or paramedic within 3 months prior to Visit 1 and until randomisation

          -  Occurence of Diabetic Ketoacidosis (DKA) within 3 months prior to Visit 1 and until
             randomisation

        Additional exclusion criteria may apply
      